{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:12:19Z","timestamp":1782951139695,"version":"3.54.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1136\/ijgc-2020-001863","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T17:40:13Z","timestamp":1602265213000},"page":"1768-1774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Phase Ib\/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer"],"prefix":"10.1016","volume":"30","clinical-trial-number":[{"clinical-trial-number":"nct00317772","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00317772","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2944-9488","authenticated-orcid":false,"given":"Anca","family":"Chelariu-Raicu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles F","family":"Levenback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane C","family":"Bodurka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J","family":"Kavanagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-001863_bb0010","author":"American Cancer Society","year":"2020","journal-title":"Key statistics for ovarian cancer"},{"key":"10.1136\/ijgc-2020-001863_bb0015","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001863_bb0020","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2002.20.5.1238","article-title":"Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer","volume":"20","author":"Dizon","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001863_bb0025","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"Naumann","year":"2011","journal-title":"Drugs"},{"key":"10.1136\/ijgc-2020-001863_bb0030","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.1997.15.6.2183","article-title":"Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer","volume":"15","author":"ten Bokkel Huinink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001863_bb0035","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-001863_bb0040","first-page":"163","article-title":"Topoisomerase-targeting antitumor drugs","volume":"989","author":"D'Arpa","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"10.1136\/ijgc-2020-001863_bb0045","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/bjc.2011.62","article-title":"The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer","volume":"104","author":"Sheng","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2020-001863_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000088","article-title":"Therapeutic value of EGFR inhibition in CRC and NSCLC: 15\u2005years of clinical evidence","volume":"1","author":"Troiani","year":"2016","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2020-001863_bb0055","first-page":"739","article-title":"The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux","volume":"61","author":"Erlichman","year":"2001","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2020-001863_bb0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.semcancer.2003.11.005","article-title":"'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC)","volume":"14","author":"Pao","year":"2004","journal-title":"Semin Cancer Biol"},{"key":"10.1136\/ijgc-2020-001863_bb0065","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","article-title":"Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer","volume":"351","author":"Cunningham","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-001863_bb0070","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1159\/000127384","article-title":"Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy","volume":"73","author":"Largillier","year":"2007","journal-title":"Oncology"},{"key":"10.1136\/ijgc-2020-001863_bb0075","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-05-0462","article-title":"Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study","volume":"11","author":"Schilder","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-001863_bb0080","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ygyno.2011.03.030","article-title":"Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory\/resistant ovarian and primary peritoneal carcinoma","volume":"122","author":"Weroha","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001863_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/IGC.0b013e31826d1438","article-title":"Expected benefits of topotecan combined with lapatinib in recurrent ovarian cancer according to biological profile: a phase 2 trial","volume":"22","author":"Lheureux","year":"2012","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-001863_bb0090","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-Line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1136\/ijgc-2020-001863_bb0095","author":"2020 ASCO Virtual Scientific Program","year":"2020","journal-title":"ASCO news release. Post-surgery osimertinib delays disease recurrence in patients with localized non-small cell lung cancer."}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401209X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2401209X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-001863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:38:39Z","timestamp":1753101519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2401209X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1048891X2401209X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-001863","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase Ib\/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-001863","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}